Library Open Repository
Bertilimumab (Cambridge Antibody Technology Group)
bertilimumab.pdf | Request a copy
Full text restricted
Available under University of Tasmania Standard License.
Cambridge Antibody Technology (CAT) is developing
bertilimumab, an anti-eotaxin-1 monoclonal antibody, for the potential treatment of allergic disorders. By September 2003, CAT had released results from phase I/II trials, and was seeking to outlicense rights for bertilimumab.
|Journal or Publication Title:||Current Opinion in Investigational Drugs|
|Page Range:||pp. 1213-1219|
|Date Deposited:||01 Apr 2008 03:00|
|Last Modified:||18 Nov 2014 03:32|
|Item Statistics:||View statistics for this item|
Actions (login required)
|Item Control Page|